Abstract
The angiogenic growth factor thymidine phosphorylase/PD-ECGF has been identified as a potential target in the development of anti-cancer drugs. This review firstly discusses the biological role of TP/PD-ECGF and its importance in the activation of 5-fluorouracil and its prodrugs. The chemistry and chemotherapeutic potential of TP/PD-ECGF inhibitors are also discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 383-392 |
| Number of pages | 10 |
| Journal | Anti-Cancer Drug Design |
| Volume | 14 |
| Issue number | 5 |
| Publication status | Published - 1999 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- 5-fluorouracil
- Angiogenesis
- Anti-cancer drugs
- PD-ECGF
- Thymidine phosphorylase
- TP inhibitors
ASJC Scopus subject areas
- Biochemistry
- General Biochemistry,Genetics and Molecular Biology
- Oncology
- Pharmacology
- Drug Discovery
- Organic Chemistry
Fingerprint
Dive into the research topics of 'The role of thymidine phosphorylase/PD-ECGF in cancer chemotherapy: A chemical perspective'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver